PDR®

54 EDITION

2000

www.pdr.net

PHYSICIANS' DESK REFERENCE®

PDR.net℠



The Official

Home of

the Physicians'

Desk Reference

on the Web

PDR.net Content and Features:

Physicians' Desk Reference®*

More than 10,000 full text articles from Medical Economics Company publications including: *Medical Economics®*, *Patient Care®* and much more...

Free MEDLINE/AIDSLINE/ CANCERLIT

PDR.net for Consumers

PDR's Getting Well Network℠

Online CME/CE

Medical Economics Company

*Access to the full, professional version of the PDR® on PDR.net is free for practicing U.S.-based physicians and physician assistants. Consumers can access drug information from the PDR *Family Guide to Prescription Drugs®* which is available for free through the PDR.net Supersite consumers' area.

healthcare information you can trust

When you need healthcare information visit the one site that offers the most – the PDR.*net* Supersite. Sponsored and maintained by one of the most respected names in health care, you can access the *Physicians' Desk Reference®* as well as thousands of professional healthcare articles from the pages of Medical Economics Company publications. Physicians also benefit from online CME, daily medical news from Reuters, and Stedman's Medical Dictionary. Consumers can take advantage of the *PDR Family Guide to Prescription Drugs®*, daily healthcare news from Reuters, as well as PDR's Getting Well Network – individual, disease-specific sites covering allergy, arthritis, breast cancer, depression, hypertension, osteoporosis, and ear infection/otitis media.



From the office, your home, or the road, the healthcare information you can trust is always within your reach.

www.pdr.net

PDR®

54

EDITION

2000

PHYSICIANS' DESK REFERENCE®

Senior Vice President, Directory Services: Paul Walsh

Director of Product Management: Mark A. Friedman
Associate Product Manager: Bill Shaughnessy
Senior Business Manager: Mark S. Ritchin
Financial Analyst: Wayne M. Soltis
Director of Sales: Dikran N. Barsamian
National Sales Manager, Pharmaceutical Sales: Anthony Sorce
National Account Manager: Don Bruccoleri
Senior Account Manager: Frank Karkowsky
Account Managers:
Marion Gray, RPh
Lawrence C. Keary
Jeffrey F. Pfohl
Suzanne E. Yarrow, RN
Electronic Sales Account Manager: Stephen M. Silverberg
National Sales Manager, Medical Economics Trade Sales: Bill Gaffney
Director of Direct Marketing: Michael Bennett
List and Production Manager: Lorraine M. Loening
Senior Marketing Analyst: Dina A. Maeder

Director, New Business Development and Professional Support Services: Mukesh Mehta, RPh
Manager, Drug Information Services: Thomas Fleming, RPh
Drug Information Specialist: Maria Deutsch, MS, RPh, CDE
Editor, Directory Services: David W. Sifton
Senior Associate Editor: Lori Murray
Director of Production: Carrie Williams
Manager of Production: Kimberly H. Vivas
Senior Production Coordinator: Amy B. Brooks
Production Coordinators: Gianna Caradonna, Maria Volpati
Data Manager: Jeffrey D. Schaefer
Senior Format Editor: Gregory J. Westley
Index Editors: Johanna M. Mazur, Robert N. Woerner
Art Associate: Joan K. Akerlind
Senior Digital Imaging Coordinator: Shawn W. Cahill
Digital Imaging Coordinator: Frank J. McElroy, III
Electronic Publishing Designer: Livio Udina
Fulfillment Manager: Stephanie DeNardi

Officers of Medical Economics Company: *President and Chief Executive Officer:* Curtis B. Allen; *Vice President, New Media:* L. Suzanne BeDell; *Vice President, Corporate Human Resources:* Pamela M. Bilash; *Vice President and Chief Information Officer:* Steven M. Bressler; *Chief Financial Officer:* Christopher Caridi; *Vice President and Controller:* Barry Gray; *Vice President, New Business Planning:* Linda G. Hope; *Vice President, Business Integration:* David A. Pitler; *Vice President, Finance:* Donna Santarpia; *Senior Vice President, Directory Services:* Paul Walsh; *Senior Vice President, Operations:* John R. Ware; *Senior Vice President, Internet Strategies:* Raymond Zoeller

Printed on recycled paper

ISBN: 1-56363-330-2

MONODOX®

℞

DOXYCYCLINE MONOHYDRATE CAPSULES

[*mon 'o-dox*]

DESCRIPTION

Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. Monodox® 100 mg and 50 mg capsules contain doxycycline monohydrate equivalent to 100 mg or 50 mg of doxycycline for oral administration. The chemical designation of the light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline.

Structural formula:



$C_{22}H_{24}N_2O_8 \cdot H_2O$ M.W.=462.46

Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Inert Ingredients: colloidal silicon dioxide; hard gelatin capsule; magnesium stearate; microcrystalline cellulose; and sodium starch glycolate.

CLINICAL PHARMACOLOGY

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.

Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:

[See table below]

	Average Observed Values
Maximum Concentration	3.61 mcg/mL (± 0.9 sd)
Time of Maximum Concentration	2.60 hr (± 1.10 sd)
Elimination Rate Constant	0.049 per hr (± 0.030 sd)
Half-Life	16.33 hr (± 4.53 sd)

Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18-22 hours) in individuals with normal and severely impaired renal function.

Hemodialysis does not alter serum half-life.

Microbiology: The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including doxycycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms. Cross-resistance of these organisms to tetracyclines is common.

While *in vitro* studies have demonstrated the susceptibility of most strains of the following microorganisms, clinical efficacy for infections other than those included in the INDICATIONS AND USAGE section has not been documented.

GRAM-NEGATIVE BACTERIA:

- *Neisseria gonorrhoeae*
- *Haemophilus ducreyi*
- *Haemophilus influenzae*
- *Yersinia pestis* (formerly *Pasteurella pestis*)
- *Francisella tularensis* (formerly *Pasteurella tularensis*)
- *Vibrio cholerae* (formerly *Vibrio comma*)
- *Bartonella bacilliformis*
- *Brucella species*

Because many strains of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended:

- *Escherichia coli*
- *Klebsiella species*
- *Enterobacter aerogenes*
- *Shigella species*
- *Acinetobacter species* (formerly *Mima* species and *Herellea* species)
- *Bacteroides* species

GRAM-POSITIVE BACTERIA:

Because many strains of the following groups of gram-positive microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Up to 44 percent of strains of *Streptococcus pyogenes* and 74 percent of *Streptococcus faecalis* have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used to treat streptococcal infections unless the organism has been demonstrated to be susceptible.

- *Streptococcus pyogenes*
- *Streptococcus pneumoniae*
- *Enterococcus* group (*Streptococcus faecalis* and *Streptococcus faecium*)
- *Alpha-hemolytic streptococci (viridans* group)

OTHER MICROORGANISMS:

- *Chlamydia psittaci*
- *Chlamydia trachomatis*
- *Ureaplasma urealyticum*
- *Borrelia recurrentis*
- *Treponema pallidum*
- *Treponema pertenue*
- *Clostridium* species
- *Fusobacterium fusiforme*
- *Actinomyces* species
- *Bacillus anthracis*
- *Propionibacterium acnes*
- *Entamoeba* species
- *Balantidium coli*

Susceptibility tests: Diffusion Techniques: Quantitative methods that require measurement of zone diameters give the most precise estimate of the susceptibility of bacteria to antimicrobial agents.

One such standard procedure[1] which has been recommended for use with disks to test susceptibility of organisms to doxycycline uses the 30-mcg tetracycline-class disk or the 30-mcg doxycycline disk. Interpretation involves the correlation of the diameter obtained in the disk test with the minimum inhibitory concentration (MIC) for tetracycline or doxycycline, respectively.

Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30-mcg tetracycline-class disk or the 30-mcg doxycycline disk should be interpreted according to the following criteria.

Zone Diameter (mm)		Interpretation
tetracycline	doxycycline	
≥19	≥16	Susceptible
15–18	13–15	Intermediate
≤14	≤12	Resistant

A report of "susceptible" indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of "intermediate" suggests that the organism would be susceptible if a high dosage is used or if the infection is confined to tissues and fluids in which high antimicrobial levels are attained. A report of "resistant" indicates that achievable concentrations are unlikely to be inhibitory, and other therapy should be selected.

Standardized procedures require the use of laboratory control organisms. The 30-mcg tetracycline-class disk or the 30-mcg doxycycline disk should give the following zone diameters:

Organism	Zone Diameter	
	tetracycline	doxycycline
E. coli ATCC 25922	18–25	18–24
S. aureus ATCC 25923	19–28	23–29

Dilution Techniques:

Use a standardized dilution method[2] (broth, agar, microdilution) or equivalent with tetracycline powder. The MIC values obtained should be interpreted according to the following criteria:

MIC (mcg/mL)	Interpretation
≤4	Susceptible
8	Intermediate
≥16	Resistant

As with standard diffusion techniques, dilution methods require the use of laboratory control organisms. Standard tetracycline powder should provide the following MIC values:

Organism	MIC (mcg/mL)
S. aureus ATCC 29213	0.25–1
E. faecalis ATCC 29212	8–32
E. coli ATCC 25922	1–4
P. aeruginosa ATCC 27853	8–32

INDICATIONS AND USAGE

Doxycycline is indicated for the treatment of the following infections:

Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.

Respiratory tract infections caused by *Mycoplasma pneumoniae.*

Lymphogranuloma venereum caused by *Chlamydia trachomatis.*

Psittacosis (omithosis) caused by *Chlamydia psittaci.*

Trachoma caused by *Chlamydia trachomatis,* although the infectious agent is not always eliminated as judged by immunofluorescence.

Inclusion conjunctivitis caused by *Chlamydia trachomatis.*

Uncomplicated urethral, endocervical or rectal infections in adults caused by *Chlamydia trachomatis.*

Nongonococcal urethritis caused by *Ureaplasma urealyticum.*

Relapsing fever due to *Borrelia recurrentis.*

Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:

Chancroid caused by *Haemophilus ducreyi.*

Plague due to *Yersinia pestis* (formerly *Pasteurella pestis*).

Tularemia due to *Francisella tularensis* (formerly *Pasteurella tularensis*).

Cholera caused by *Vibrio cholerae* (formerly *Vibrio comma*).

Campylobacter fetus infections caused by *Campylobacter fetus* (formerly *Vibrio fetus*).

Brucellosis due to *Brucella* species (in conjunction with streptomycin).

Bartonellosis due to *Bartonella bacilliformis.*

Granuloma inguinale caused by *Calymmatobacterium granulomatis.*

Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.

Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:

Escherichia coli

Enterobacter aerogenes (formerly *Aerobacter aerogenes*)

Shigella species

Acinetobacter species (formerly *Mima* species and *Herellea* species)

Respiratory tract infections caused by *Haemophilus influenzae.*

Respiratory tract and urinary tract infections caused by *Klebsiella species.*

Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

Upper respiratory infections caused by *Streptococcus pneumoniae* (formerly *Diplococcus pneumoniae*).

Skin and skin structure infections caused by *Staphylococcus aureus.* Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections.

When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:

Uncomplicated gonorrhea caused by *Neisseria gonorrhoeae.*

Syphilis caused by *Treponema pallidum.*

Yaws caused by *Treponema pertenue.*

Listeriosis due to Listeria monocytogenes.

Anthrax due to *Bacillus anthracis.*

Vincent's infection caused by *Fusobacterium fusiforme.*

Actinomycosis caused by *Actinomyces israelii.*

Infections caused by *Clostridium* species.

In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.

In severe acne, doxycycline may be useful adjunctive therapy.

CONTRAINDICATIONS

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

WARNINGS

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported.

TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.

The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

PRECAUTIONS

General:

As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.

Bulging fontanels in infants and benign intracranial hypertension in adults have been reported in individuals receiving tetracyclines. These conditions disappeared when the

Time (hr):	0.5	1.0	1.5	2.0	3.0	4.0	8.0	12.0	24.0	48.0	72.0
Conc.	1.02	2.26	2.67	3.01	3.16	3.03	2.03	1.62	0.95	0.37	0.15

Incision and drainage or othe
be performed in conjunction
indicated.

Laboratory tests: In vener
syphilis is suspected, a dark
done before treatment is star
peated monthly for at least fc
In long-term therapy, periodi
gan systems, including hem
studies should be performed.

Drug interactions: Because
to depress plasma prothrombi
anticoagulant therapy may r
of their anticoagulant dosage
Since bacteriostatic drugs ma
dal action of penicillin, it is a
cyclines in conjunction with
Absorption of tetracyclines is
ing aluminum, calcium, or m
preparations.
Barbiturates, carbamazepine
half-life of doxycycline.
The concurrent use of tetracy
been reported to result in fai
Concurrent use of tetracyclin
tives less effective.

Drug/laboratory test interac
nary catecholamine levels r
with the fluorescence test.

Carcinogenesis, mutagenesis
term studies in animals to ev
tial of doxycycline have not b
has been evidence of oncoge
with related antibiotics, oxyt
tary tumors) and minocyclin
although mutagenicity studi
conducted, positive results i
says have been reported for r
oxytetracycline). Doxycycline
levels as high as 250 mg/kg
the fertility of female rats.
been studied.

Pregnancy: Pregnancy Cat

Labor and Delivery: The
and delivery is unknown.

Nursing mothers: Tetracyc
lactating women who are t
cause of the potential for se
ing infants from the tetra
made whether to discontin
drug, taking into account th
mother. (See **WARNINGS**).

Pediatric Use: See **WARN**
MINISTRATION sections.

ADVERSE REACTIONS

Due to oral doxycycline's vir
effects to the lower bowel, p
infrequent. The following a
served in patients receiving

Gastrointestinal: Anorexi
glossitis, dysphagia, enteroc
(with monilial overgrowth)
reactions have been caused
administration of tetracycli
tis and esophageal ulcerat
tients receiving capsule and
racycline class. Most of the
mediately before going
ADMINISTRATION).

Skin: Maculopapular and
tive dermatitis has been re
sensitivity is discussed abo

Renal toxicity: Rise in BU
parently dose related. (See

Hypersensitivity reactions
ma, anaphylaxis, anaphyla
exacerbation of systemic lu

Blood: Hemolytic anemia,
and eosinophilia have been

Other: Bulging fontanels
pertension in adults. (See
When given over prolonged
reported to produce brown
of the thyroid gland. No a
are known to occur.

OVERDOSAGE

In case of overdosage, disc
tomatically and institute
does not alter serum half-l
in treating cases of overdo

DOSAGE AND ADMINIS

THE USUAL DOSAGE AN
TRATION OF DOXYCYCL
THE OTHER TETRACYC
OMMENDED DOSAGE
CREASED INCIDENCE O

Adults: The usual dose of
first day of treatment (adn

ed for the treatment of infections
am-negative microorganisms:
nophilus ducreyi.
stis (formerly *Pasteurella pestis*),
ella tularensis (formerly *Pasteu-*

holerae (formerly *Vibrio comma*),
tions caused by *Campylobacter fe-*

lla species (in conjunction with

nella bacilliformis.
ed by *Calymmatobacterium gran-*

the following groups of microor-
to be resistant to doxycycline, cul-
ting are recommended.
or treatment of infections caused
ative microorganisms, when bac-
appropriate susceptibility to the

rmerly *Aerobacter aerogenes*)

nerly *Mima* species and *Herellea*

ons caused by *Haemophilus in-*

nary tract infections caused by

or treatment of infections caused
tive microorganisms when bacte-
appropriate susceptibility to the

as caused by *Streptococcus pneu-*
cus pneumoniae).
fections caused by *Staphylococcus*
the drug of choice in the treat-
rlococcal infections.
ndicated, doxycycline is an alter-
nt of the following infections:
caused by *Neisseria gonorrhoeae.*
ema pallidum.
a pertenue.
monocytogenes.
nthracis.
by *Fusobacterium fusiforme.*
actinomyces israelii.
ridium species.
sis, doxycycline may be a useful

e may be useful adjunctive ther-

d in persons who have shown hy-
tetracyclines.

THE TETRACYCLINE CLASS
ELOPMENT (LAST HALF OF
, AND CHILDHOOD TO THE
CAUSE PERMANENT DISCOL-
H (YELLOW-GRAY-BROWN).
ore common during long-term use
bserved following repeated short-
plasia has also been reported.
, THEREFORE, SHOULD NOT
HE GROUP UNLESS OTHER
Y TO BE EFFECTIVE OR ARE

ble calcium complex in any bone-
e in the fibula growth rate has
ures given oral tetracycline in
hours. This reaction was shown
drug was discontinued.
indicate that tetracyclines cross
fetal tissues, and can have toxic
stus (often related to retardation
Evidence of embryo toxicity has
ed early in pregnancy. If any tet-
gnancy or if the patient becomes
se drugs, the patient should be
azard to the fetus.
the tetracyclines may cause an
o date indicate that this does not
ycline in patients with impaired

d by an exaggerated sunburn re-
n some individuals taking tetra-
exposed to direct sunlight or ul-
vised that this reaction can occur
d treatment should be discontin-
skin erythema.

eparations, use of this drug may
n-susceptible organisms, includ-
occurs, the antibiotic should be
te therapy instituted.
s and benign intracranial hyper-
n reported in individuals receiv-
nditions disappeared when the

Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy when indicated.

Laboratory tests: In venereal disease when coexistent syphilis is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months.

In long-term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.

Drug interactions: Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

Drug/laboratory test interactions: False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

Carcinogenesis, mutagenesis, impairment of fertility: Long-term studies in animals to evaluate the carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with related antibiotics, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in *in vitro* mammalian cell assays have been reported for related antibiotics (tetracycline, oxytetracycline). Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.

Pregnancy: Pregnancy Category D. (See **WARNINGS**).

Labor and Delivery: The effect of tetracyclines on labor and delivery is unknown.

Nursing mothers: Tetracyclines are present in the milk of lactating women who are taking a drug in this class. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. (See **WARNINGS**).

Pediatric Use: See **WARNINGS** and **DOSAGE AND ADMINISTRATION** sections.

ADVERSE REACTIONS

Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines.

Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See **DOSAGE AND ADMINISTRATION**).

Skin: Maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See **WARNINGS**.)

Renal toxicity: Rise in BUN has been reported and is apparently dose related. (See **WARNINGS**.)

Hypersensitivity reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus.

Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported with tetracyclines.

Other: Bulging fontanels in infants and intracranial hypertension in adults. (See **PRECAUTIONS—General**.)

When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.

OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life, and it would not be of benefit in treating cases of overdosage.

DOSAGE AND ADMINISTRATION

THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.

Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours or 50 mg every 6 hours) followed by a maintenance dose of 100 mg/day. The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.

For pediatric patients above eight years of age: The recommended dosage schedule for pediatric patients weighing 100 pounds or less is 2 mg/lb of body weight divided into two doses on the first day of treatment, followed by 1 mg/lb of body weight given as a single daily dose or divided into two doses, on subsequent days. For more severe infections, up to 2 mg/lb of body weight may be used. For pediatric patients over 100 lbs the usual adult dose should be used.

Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.

Acute epididymo-orchitis caused by *N. gonorrhoeae*: 100 mg, by mouth, twice a day for at least 10 days.

Primary and secondary syphilis: 300 mg a day in divided doses for at least 10 days.

Uncomplicated urethral, endocervical, or rectal infection in adults caused by *Chlamydia trachomatis*: 100 mg, by mouth, twice a day for at least 7 days.

Nongonococcal urethritis caused by *C. trachomatis* and *U. urealyticum*: 100 mg, by mouth, twice a day for at least 7 days.

Acute epididymo-orchitis caused by *C. trachomatis*: 100 mg, by mouth, twice a day for at least 10 days.

When used in streptococcal infections, therapy should be continued for 10 days.

Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See **ADVERSE REACTIONS**). If gastric irritation occurs, doxycycline may be given with food. Ingestion of a high fat meal has been shown to delay the time to peak plasma concentrations by an average of one hour and 20 minutes. However, in the same study, food enhanced the average peak concentration by 7.5% and the area under the curve by 5.7%.

HOW SUPPLIED

MONODOX® 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription "MONODOX 50" in brown and "M 260" in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.

MONODOX® 50 mg is available in: Bottles of 100 capsules, NDC 55515-260-06. MONODOX® 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 100" in white and "M 259" in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline. MONODOX® 100 mg is available in: Bottles of 50 capsules, NDC 55515-259-04 and in bottles of 250 capsules, NDC 55515-259-07.

STORE AT CONTROLLED ROOM TEMPERATURE 15°–30°C (59°–86°F). PROTECT FROM LIGHT.

ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY

Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO_4, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO_4, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.

Minocycline, tetracycline PO_4, methacycline, doxycycline, tetracycline base, oxytetracycline HCl and tetracycline HCl were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.

Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.

REFERENCES:

1. National Committee for Clinical Laboratory Standards, *Performance Standards for Antimicrobial Disk Susceptibility Tests*, Fourth Edition. Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7 NCCLS, Villanova, PA, April 1990.
2. National Committee for Clinical Laboratory Standards, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*, Second Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8 NCCLS, Villanova, PA, April 1990.

Rx Only

Manufactured for
OCLASSEN PHARMACEUTICALS
A Division of Watson Labs. Inc., Corona, CA 91720
by Vintage Pharmaceuticals, Inc., Charlotte, N.C.
Revised April 28, 1998 02-18391/R7

Shown in Product Identification Guide, page 327

OHMEDA

Pharmaceutical Products Division Inc.
(see BAXTER PHARMACEUTICAL PRODUCTS INC.)

Organon Inc.

375 MT. PLEASANT AVE.
WEST ORANGE, NJ 07052

Direct Inquiries to:
(973) 325-4500

Currently available products are listed below. For complete product line information and price lists, direct inquiries to Organon Inc. Customer Service. For specific product information, contact Organon Inc. Medical Services Department.

ARDUAN®

(pipecuronium bromide) for injection

HOW SUPPLIED

10 mL vials/10 mg—boxes of 6 vials—NDC-0052-0446-36

TICE® BCG, BCG Live

BCG VACCINE USP
(for Intravesical use)

Distributed by Organon Inc.
(See page 2111 complete product information.)

CALDEROL®

[*kal-dah 'rol*]
(calcifediol capsules, USP)

HOW SUPPLIED

20 µg (white, soft elastic capsules) bottle of 60
50 µg (orange, soft elastic capsules) bottle of 60
Shown in Product Identification Guide, page 327

CORTROSYN®

[*cōr-trō-sin*]
(cosyntropin) for injection
FOR DIAGNOSTIC USE ONLY

DESCRIPTION

Cortrosyn® (cosyntropin) for injection is a sterile lyophilized powder in vials containing 0.25mg of Cortrosyn® and 10mg of mannitol to be reconstituted with 1mL sodium chloride for injection, USP as solvent. Administration is by intravenous or intramuscular injection. Cosyntropin is α 1–24 corticotropin, a synthetic subunit of ACTH. It is an open chain polypeptide containing, from the N terminus, the first 24 of the 39 amino acids of natural ACTH. The sequence of amino acids in the 1–24 compound is as follows:

Ser	Tyr	Ser	Met	Glu	His	Phe	Arg	Trp	Gly	Lys
1.	2	3	4	5	6	7	8	9	10	11

Pro	Val	Gly	Lys	Lys	Arg	Arg	Pro	Val	Lys	Val
12	13	14	15	16	17	18	19	20	21	22

Tyr	Pro
23	24

CLINICAL PHARMACOLOGY

Cortrosyn® (cosyntropin) for injection exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1–20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residue. For example, the decrement from 20 to 19 results in a 70% loss of potency.

The pharmacologic profile of Cortrosyn® is similar to that of purified natural ACTH. It has been established that 0.25 mg of Cortrosyn® will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. This dose of Cortrosyn® will produce maximal secretion of 17-OH corticosteroids, 17-ketosteroids and/or 17-ketogenic steroids.

The extra-adrenal effects which natural ACTH and Cortrosyn® have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance.

Animal, human and synthetic ACTH (1–39) which all contain 39 amino acids exhibit similar immunologic activity.

Continued on next page

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.